CAS developed anti-SARS-CoV-2 drug candidate enters clinical trial in the US

(Chinese Academy of Sciences Headquarters) DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.